New device may reduce radiation exposure to patients with liver cancer

Share this content:

the ONA take:

AlluraClarity, an FDA-approved X-ray guidance device, has the potential to reduce radiation exposure in patients with liver cancer undergoing intra-arterial therapy (IAT), according to a report to be presented at the Radiological Society of North America annual meeting in Chicago.

In a clinical trial, Jean-Francois Geschwind, MD, and fellow researchers at Johns Hopkins University School of Medicine and Kimmel Cancer Center used the device on 50 patients, the researchers found that it was able to reduce exposure by up to 80 percent compared to standard X-ray platforms for IAT. In addition, AlluraClarity produced images that were just as clear as the standard system.

Dr. Geschwind believes that the novel platform will be especially useful in patients who require repeat therapy and are especially vulnerable to radiation such as children, as well as physicians who are regularly exposed to radiation procedures.

AlluraClarity uses a series of real-time image processing algorithms in order to achieve high quality images that require lower radiation power. It is developed by Philips Healthcare.

Hepatocellular carcinoma with no cirrhosis
AlluraClarity has the potential to reduce radiation exposure in patients with liver cancer.
Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy (IAT) for liver cancer.
READ FULL ARTICLE From Medical News Today
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs